AVXL earnings: next report 2026-07-23, real EPS beat/miss history, analyst consensus Buy, P/E -5.50. Updated 2026-07-23.
Anavex Life Sciences (AVXL) Research Hub
Anavex Life Sciences (AVXL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.62 USD (-4.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.50, market cap 0.23B. This hub links to the full technical, earnings and options research available for AVXL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.62 USD (-4.73%) |
| 52-week range | 2.3 USD – 3.68 USD |
| Trend regime | Range |
| 14-day RSI | 32.7 (Bearish) |
| Trailing P/E | -5.50 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-23 |
Available research for AVXL
Covered Call on AVXL: how it works, illustrative setup around the real 2.62 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AVXL: how it works, illustrative setup around the real 2.62 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AVXL: how it works, illustrative setup around the real 2.62 USD price, max profit/loss, breakeven and when to use it. Educational.
AVXL technical analysis: range, last 2.62 USD, RSI 32.7, 52w range 2.3 USD–3.68 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AVXL in?
Anavex Life Sciences (AVXL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AVXL in an uptrend or downtrend?
As of 2026-09-11, AVXL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AVXL's trailing P/E ratio?
AVXL's trailing P/E is -5.50, with a market cap of 0.23B. See the earnings research page for full valuation detail.
When does AVXL next report earnings?
AVXL is next scheduled to report earnings on 2026-07-23, with a consensus EPS estimate of -0.07 USD.